ATLANTA, Dec. 30, 2024 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Caribou Biosciences, Inc. (“Caribou” or the “Company”) (NASDAQ: CRBU). The lawsuit alleges that Defendants made materially false and/or misleading statements, and/or failed to disclose material adverse facts about Caribou’s business, operations, and prospects, including allegations that: (i) they overstated CB-010’s safety, efficacy, and durability relative to approved autologous chimeric antigen receptor-T ...